scispace - formally typeset
N

Nora D. Volkow

Researcher at National Institute on Drug Abuse

Publications -  1038
Citations -  121498

Nora D. Volkow is an academic researcher from National Institute on Drug Abuse. The author has contributed to research in topics: Dopamine & Addiction. The author has an hindex of 165, co-authored 958 publications receiving 107463 citations. Previous affiliations of Nora D. Volkow include National Institutes of Health & North Shore University Hospital.

Papers
More filters
Journal ArticleDOI

Brain lesions disrupting addiction map to a common human brain circuit

TL;DR: Lesions disrupting smoking addiction occurred in many different brain locations but were characterized by a specific pattern of brain connectivity as discussed by the authors , which involved positive connectivity to the dorsal cingulate, lateral prefrontal cortex, and insula and negative connectivity to medial prefrontal and temporal cortex.
Journal ArticleDOI

Socioeconomic status is associated with striatal dopamine D2/D3 receptors in healthy volunteers but not in cocaine abusers

TL;DR: It is confirmed that SES is associated with striatal D2/D3R availability in healthy human volunteers, however, reductions in D2-D3r availability in cocaine abusers may be driven by factors other than SES such as chronic cocaine exposure.
Journal ArticleDOI

Long-term optical imaging of neurovascular coupling in mouse cortex using GCaMP6f and intrinsic hemodynamic signals.

TL;DR: By combining the use of a genetically‐encoded calcium indicator with optical techniques, a longitudinal multimodal optical imaging platform (MIP) is developed that enabled time‐lapse tracking of NVC over a relatively large field of view in the mouse somatosensory cortex at single cell and single vessel resolutions.
Journal ArticleDOI

Methadone-Involved Overdose Deaths in the US Before and After Federal Policy Changes Expanding Take-Home Methadone Doses From Opioid Treatment Programs.

TL;DR: To facilitate access to methadone treatment from opioid treatment programs (OTPs) during the COVID-19 pandemic, the Substance Abuse and Mental Health Services Administration allowed states to request blanket exceptions to provide up to 28 and 14 days of take-home methadones for stable and less stable patients, respectively.